Martin Zamora
Concepts (286)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Transplantation | 32 | 2023 | 313 | 5.480 |
Why?
| | Cytomegalovirus Infections | 7 | 2012 | 192 | 1.720 |
Why?
| | Antiviral Agents | 12 | 2023 | 744 | 1.420 |
Why?
| | Respiratory Syncytial Virus Infections | 4 | 2023 | 128 | 1.280 |
Why?
| | Lung Diseases | 7 | 2017 | 767 | 1.090 |
Why?
| | Bronchiolitis Obliterans | 7 | 2015 | 69 | 0.780 |
Why?
| | Ganciclovir | 5 | 2012 | 53 | 0.770 |
Why?
| | Respiratory Syncytial Virus, Human | 2 | 2023 | 74 | 0.760 |
Why?
| | Postoperative Complications | 9 | 2015 | 2654 | 0.730 |
Why?
| | Heart Transplantation | 7 | 2019 | 754 | 0.630 |
Why?
| | alpha 1-Antitrypsin Deficiency | 2 | 2018 | 67 | 0.580 |
Why?
| | Graft Rejection | 10 | 2019 | 624 | 0.560 |
Why?
| | Pneumonia, Viral | 1 | 2023 | 373 | 0.560 |
Why?
| | Pulmonary Medicine | 1 | 2017 | 85 | 0.520 |
Why?
| | Graft Survival | 6 | 2019 | 535 | 0.500 |
Why?
| | Lung | 11 | 2017 | 4060 | 0.490 |
Why?
| | Regeneration | 1 | 2017 | 197 | 0.480 |
Why?
| | Sirolimus | 3 | 2018 | 276 | 0.470 |
Why?
| | Diltiazem | 1 | 2014 | 29 | 0.440 |
Why?
| | Bronchial Arteries | 2 | 2010 | 12 | 0.420 |
Why?
| | RNA, Small Interfering | 2 | 2015 | 622 | 0.390 |
Why?
| | Transplant Recipients | 1 | 2014 | 184 | 0.380 |
Why?
| | Transplantation, Homologous | 11 | 2019 | 416 | 0.370 |
Why?
| | Organ Transplantation | 3 | 2018 | 250 | 0.370 |
Why?
| | Pulmonary Circulation | 2 | 2010 | 429 | 0.360 |
Why?
| | Polymorphism, Genetic | 1 | 2014 | 660 | 0.350 |
Why?
| | Virus Diseases | 2 | 2011 | 212 | 0.340 |
Why?
| | Patient Selection | 6 | 2015 | 696 | 0.340 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2012 | 203 | 0.330 |
Why?
| | Herpesviridae Infections | 1 | 2011 | 147 | 0.330 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2012 | 367 | 0.330 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2011 | 98 | 0.330 |
Why?
| | RNA Interference | 2 | 2013 | 469 | 0.320 |
Why?
| | Pulmonary Emphysema | 4 | 2015 | 288 | 0.310 |
Why?
| | Respiratory Tract Infections | 2 | 2011 | 390 | 0.300 |
Why?
| | Societies, Medical | 4 | 2018 | 820 | 0.300 |
Why?
| | Treatment Outcome | 10 | 2023 | 10811 | 0.290 |
Why?
| | Cytomegalovirus | 2 | 2004 | 157 | 0.260 |
Why?
| | Gene Expression Regulation | 3 | 2014 | 2607 | 0.250 |
Why?
| | Immunosuppressive Agents | 5 | 2019 | 890 | 0.240 |
Why?
| | Humans | 42 | 2023 | 137585 | 0.240 |
Why?
| | Vasculitis | 1 | 2005 | 66 | 0.230 |
Why?
| | Capillaries | 1 | 2005 | 108 | 0.230 |
Why?
| | Autoantibodies | 2 | 2013 | 1496 | 0.230 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 5 | 2015 | 1040 | 0.230 |
Why?
| | Drug Resistance, Viral | 3 | 2011 | 116 | 0.220 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2004 | 132 | 0.210 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 2 | 2018 | 30 | 0.210 |
Why?
| | Waiting Lists | 3 | 2015 | 266 | 0.210 |
Why?
| | Reperfusion Injury | 3 | 2017 | 279 | 0.210 |
Why?
| | Heart-Lung Transplantation | 2 | 2014 | 14 | 0.200 |
Why?
| | Pneumonectomy | 2 | 2018 | 152 | 0.200 |
Why?
| | Risk Factors | 7 | 2013 | 10388 | 0.190 |
Why?
| | Consensus | 2 | 2016 | 683 | 0.190 |
Why?
| | Evidence-Based Medicine | 1 | 2005 | 740 | 0.170 |
Why?
| | CD11b Antigen | 1 | 2019 | 61 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2019 | 67 | 0.160 |
Why?
| | Stem Cell Transplantation | 1 | 2019 | 176 | 0.150 |
Why?
| | Transplantation Tolerance | 1 | 2018 | 36 | 0.150 |
Why?
| | Middle Aged | 15 | 2015 | 33479 | 0.140 |
Why?
| | Primary Graft Dysfunction | 2 | 2017 | 32 | 0.140 |
Why?
| | Endothelial Cells | 2 | 2013 | 785 | 0.140 |
Why?
| | Bronchoalveolar Lavage Fluid | 4 | 2020 | 652 | 0.130 |
Why?
| | Transplantation, Heterotopic | 2 | 2014 | 18 | 0.130 |
Why?
| | Respiratory Function Tests | 2 | 2010 | 600 | 0.130 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2014 | 1091 | 0.120 |
Why?
| | DNA, Mitochondrial | 1 | 2017 | 200 | 0.120 |
Why?
| | Syndrome | 3 | 2015 | 358 | 0.120 |
Why?
| | Immune Tolerance | 1 | 2018 | 363 | 0.120 |
Why?
| | Congresses as Topic | 1 | 2017 | 233 | 0.120 |
Why?
| | Adult | 10 | 2023 | 37929 | 0.120 |
Why?
| | Frailty | 1 | 2018 | 170 | 0.120 |
Why?
| | International Cooperation | 1 | 2016 | 198 | 0.120 |
Why?
| | Male | 18 | 2015 | 67762 | 0.120 |
Why?
| | Interleukin-18 | 2 | 2013 | 236 | 0.120 |
Why?
| | Fas Ligand Protein | 1 | 2014 | 60 | 0.110 |
Why?
| | Tissue Donors | 2 | 2016 | 425 | 0.110 |
Why?
| | Asphyxia | 1 | 2014 | 20 | 0.110 |
Why?
| | Female | 18 | 2019 | 73304 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2014 | 5131 | 0.110 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2014 | 15 | 0.110 |
Why?
| | Receptors, Steroid | 1 | 2014 | 50 | 0.110 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2014 | 48 | 0.110 |
Why?
| | Everolimus | 1 | 2014 | 91 | 0.110 |
Why?
| | Health Resources | 1 | 2015 | 120 | 0.110 |
Why?
| | Anastomosis, Surgical | 2 | 2013 | 153 | 0.110 |
Why?
| | Tobacco Smoke Pollution | 2 | 2013 | 261 | 0.110 |
Why?
| | Tissue and Organ Procurement | 2 | 2015 | 321 | 0.100 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2014 | 88 | 0.100 |
Why?
| | Tissue Distribution | 1 | 2014 | 332 | 0.100 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2014 | 59 | 0.100 |
Why?
| | CD146 Antigen | 1 | 2013 | 42 | 0.100 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2015 | 301 | 0.100 |
Why?
| | Perfusion | 1 | 2014 | 213 | 0.100 |
Why?
| | Demography | 1 | 2014 | 291 | 0.100 |
Why?
| | Animals | 13 | 2019 | 36940 | 0.100 |
Why?
| | Calcineurin Inhibitors | 2 | 2019 | 72 | 0.100 |
Why?
| | Immunocompromised Host | 2 | 2011 | 202 | 0.100 |
Why?
| | Practice Guidelines as Topic | 2 | 2018 | 1587 | 0.090 |
Why?
| | Vasodilator Agents | 1 | 2014 | 331 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 900 | 0.090 |
Why?
| | Predictive Value of Tests | 3 | 2013 | 2031 | 0.090 |
Why?
| | Metabolic Clearance Rate | 1 | 2012 | 115 | 0.090 |
Why?
| | Mice, Inbred BALB C | 4 | 2019 | 1272 | 0.090 |
Why?
| | Injections, Intravenous | 1 | 2012 | 206 | 0.090 |
Why?
| | Seroepidemiologic Studies | 1 | 2012 | 165 | 0.090 |
Why?
| | Liver Transplantation | 1 | 2018 | 871 | 0.090 |
Why?
| | Cytokines | 2 | 2010 | 2085 | 0.080 |
Why?
| | Viral Vaccines | 1 | 2011 | 98 | 0.080 |
Why?
| | Polymerase Chain Reaction | 2 | 2004 | 1062 | 0.080 |
Why?
| | Neprilysin | 1 | 2010 | 47 | 0.080 |
Why?
| | Airway Remodeling | 1 | 2010 | 64 | 0.080 |
Why?
| | Cell Communication | 1 | 2012 | 315 | 0.080 |
Why?
| | Double-Blind Method | 2 | 2015 | 1993 | 0.080 |
Why?
| | Gene Expression | 1 | 2014 | 1502 | 0.080 |
Why?
| | Respiration, Artificial | 1 | 2014 | 645 | 0.080 |
Why?
| | CD4 Antigens | 1 | 2010 | 141 | 0.080 |
Why?
| | Cross-Over Studies | 1 | 2012 | 564 | 0.080 |
Why?
| | Preoperative Care | 1 | 2012 | 362 | 0.080 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2010 | 173 | 0.080 |
Why?
| | Adoptive Transfer | 1 | 2010 | 219 | 0.080 |
Why?
| | Length of Stay | 1 | 2015 | 1215 | 0.080 |
Why?
| | Cost of Illness | 1 | 2011 | 308 | 0.080 |
Why?
| | Pulmonary Artery | 2 | 2012 | 1086 | 0.080 |
Why?
| | Genotype | 1 | 2014 | 1916 | 0.080 |
Why?
| | Administration, Inhalation | 1 | 2010 | 688 | 0.070 |
Why?
| | Blood Specimen Collection | 1 | 2008 | 41 | 0.070 |
Why?
| | Regional Blood Flow | 1 | 2010 | 474 | 0.070 |
Why?
| | Referral and Consultation | 1 | 2014 | 786 | 0.070 |
Why?
| | Pulmonary Fibrosis | 2 | 2013 | 402 | 0.070 |
Why?
| | Bacteriological Techniques | 1 | 2008 | 73 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 976 | 0.070 |
Why?
| | C-Reactive Protein | 1 | 2010 | 410 | 0.070 |
Why?
| | Macrophages, Alveolar | 2 | 2013 | 391 | 0.070 |
Why?
| | Biomarkers | 3 | 2014 | 4149 | 0.070 |
Why?
| | Cyclosporine | 2 | 2019 | 268 | 0.070 |
Why?
| | Recurrence | 1 | 2011 | 1060 | 0.070 |
Why?
| | Body Temperature | 1 | 2008 | 222 | 0.070 |
Why?
| | Macrophages | 2 | 2013 | 1547 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2057 | 0.070 |
Why?
| | Trachea | 2 | 2007 | 237 | 0.070 |
Why?
| | Fever | 1 | 2008 | 306 | 0.070 |
Why?
| | Mice | 9 | 2019 | 17787 | 0.070 |
Why?
| | Time Factors | 5 | 2015 | 6828 | 0.060 |
Why?
| | Nurse Practitioners | 1 | 2008 | 138 | 0.060 |
Why?
| | Terminology as Topic | 1 | 2007 | 216 | 0.060 |
Why?
| | Bacteremia | 1 | 2008 | 214 | 0.060 |
Why?
| | Mice, Inbred C57BL | 4 | 2019 | 5757 | 0.060 |
Why?
| | Cryptogenic Organizing Pneumonia | 1 | 2005 | 19 | 0.060 |
Why?
| | Prognosis | 1 | 2014 | 4030 | 0.060 |
Why?
| | Tissue Transplantation | 1 | 2005 | 10 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1313 | 0.060 |
Why?
| | CD40 Ligand | 1 | 2005 | 41 | 0.060 |
Why?
| | Antibodies, Monoclonal | 2 | 2018 | 1430 | 0.060 |
Why?
| | Survival | 1 | 2004 | 38 | 0.060 |
Why?
| | Mice, Inbred C3H | 2 | 2018 | 269 | 0.060 |
Why?
| | Aged | 7 | 2014 | 23961 | 0.050 |
Why?
| | Rats | 4 | 2013 | 5647 | 0.050 |
Why?
| | Drug Resistance | 1 | 2004 | 169 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2004 | 171 | 0.050 |
Why?
| | Registries | 1 | 2012 | 2035 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2012 | 1996 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2005 | 786 | 0.050 |
Why?
| | Quality Assurance, Health Care | 1 | 2005 | 322 | 0.050 |
Why?
| | Torsion Abnormality | 1 | 2003 | 16 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 3 | 2013 | 2486 | 0.050 |
Why?
| | Capillary Permeability | 2 | 2013 | 145 | 0.050 |
Why?
| | Hypoxia | 1 | 2010 | 1112 | 0.050 |
Why?
| | Cross-Sectional Studies | 1 | 2014 | 5472 | 0.050 |
Why?
| | Respiratory Mucosa | 1 | 2005 | 321 | 0.050 |
Why?
| | Fibrosis | 1 | 2005 | 552 | 0.050 |
Why?
| | Incidence | 1 | 2009 | 2804 | 0.050 |
Why?
| | Prevalence | 1 | 2009 | 2734 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2018 | 2167 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2007 | 927 | 0.040 |
Why?
| | Genomics | 1 | 2006 | 795 | 0.040 |
Why?
| | Polyphosphates | 1 | 2020 | 37 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2013 | 86 | 0.040 |
Why?
| | Transplantation Immunology | 2 | 2013 | 34 | 0.040 |
Why?
| | Neutrophils | 1 | 2006 | 1238 | 0.040 |
Why?
| | Young Adult | 3 | 2014 | 13209 | 0.040 |
Why?
| | Cell Line | 3 | 2013 | 2847 | 0.040 |
Why?
| | Early Diagnosis | 2 | 2013 | 242 | 0.040 |
Why?
| | Ribavirin | 1 | 2020 | 91 | 0.040 |
Why?
| | Abatacept | 1 | 2019 | 53 | 0.040 |
Why?
| | Mice, Knockout | 3 | 2013 | 3015 | 0.040 |
Why?
| | Prospective Studies | 1 | 2012 | 7604 | 0.040 |
Why?
| | Case-Control Studies | 3 | 2013 | 3556 | 0.040 |
Why?
| | Allografts | 1 | 2019 | 146 | 0.040 |
Why?
| | Adolescent | 4 | 2014 | 21513 | 0.040 |
Why?
| | Mice, Inbred Strains | 2 | 2013 | 409 | 0.040 |
Why?
| | CD28 Antigens | 1 | 2018 | 53 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2019 | 148 | 0.040 |
Why?
| | Health Care Rationing | 1 | 2018 | 59 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2013 | 1738 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2015 | 15657 | 0.030 |
Why?
| | Sensitivity and Specificity | 3 | 2008 | 1946 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2004 | 1774 | 0.030 |
Why?
| | Cardiomyopathies | 1 | 2019 | 350 | 0.030 |
Why?
| | DNA Repair | 1 | 2017 | 231 | 0.030 |
Why?
| | Acute Disease | 2 | 2010 | 1007 | 0.030 |
Why?
| | Isoantibodies | 1 | 2016 | 60 | 0.030 |
Why?
| | Stem Cells | 1 | 2019 | 594 | 0.030 |
Why?
| | Genes, RAG-1 | 1 | 2014 | 12 | 0.030 |
Why?
| | Cell Movement | 2 | 2012 | 967 | 0.030 |
Why?
| | DNA Damage | 1 | 2017 | 420 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2017 | 622 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2018 | 1142 | 0.030 |
Why?
| | Tidal Volume | 1 | 2014 | 86 | 0.030 |
Why?
| | Positive-Pressure Respiration | 1 | 2014 | 80 | 0.030 |
Why?
| | Chemokine CCL5 | 1 | 2013 | 43 | 0.030 |
Why?
| | Pulmonary Edema | 1 | 2013 | 108 | 0.030 |
Why?
| | Gene Deletion | 1 | 2014 | 391 | 0.030 |
Why?
| | Aorta, Abdominal | 1 | 2013 | 46 | 0.030 |
Why?
| | Patient Admission | 1 | 2015 | 197 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 71 | 0.020 |
Why?
| | Neck | 1 | 2013 | 101 | 0.020 |
Why?
| | Inhalation Exposure | 1 | 2013 | 105 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2018 | 828 | 0.020 |
Why?
| | Abdomen | 1 | 2013 | 125 | 0.020 |
Why?
| | Rats, Nude | 1 | 2012 | 26 | 0.020 |
Why?
| | Fluoresceins | 1 | 2012 | 47 | 0.020 |
Why?
| | History, 21st Century | 1 | 2013 | 213 | 0.020 |
Why?
| | Cardiomegaly | 1 | 2013 | 175 | 0.020 |
Why?
| | Tobacco Products | 1 | 2013 | 138 | 0.020 |
Why?
| | History, 20th Century | 1 | 2013 | 325 | 0.020 |
Why?
| | Cell Death | 1 | 2013 | 374 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2013 | 382 | 0.020 |
Why?
| | Child | 1 | 2011 | 21935 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2012 | 198 | 0.020 |
Why?
| | Transfection | 1 | 2013 | 945 | 0.020 |
Why?
| | Aorta, Thoracic | 1 | 2013 | 267 | 0.020 |
Why?
| | Survival Rate | 1 | 2015 | 1972 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2013 | 545 | 0.020 |
Why?
| | Myocytes, Cardiac | 1 | 2014 | 526 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2012 | 321 | 0.020 |
Why?
| | H-2 Antigens | 1 | 2010 | 115 | 0.020 |
Why?
| | United States | 2 | 2018 | 14841 | 0.020 |
Why?
| | Myocardium | 1 | 2014 | 1002 | 0.020 |
Why?
| | Oximetry | 1 | 2010 | 96 | 0.020 |
Why?
| | Bronchoscopy | 1 | 2010 | 223 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2008 | 115 | 0.020 |
Why?
| | Patient Discharge | 1 | 2015 | 897 | 0.020 |
Why?
| | International Agencies | 1 | 2007 | 35 | 0.020 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2008 | 93 | 0.020 |
Why?
| | Receptors, Interleukin-8B | 1 | 2007 | 26 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1226 | 0.020 |
Why?
| | Pulmonary Alveoli | 1 | 2010 | 405 | 0.020 |
Why?
| | Weight Loss | 1 | 2013 | 787 | 0.020 |
Why?
| | Decompression, Surgical | 1 | 2008 | 106 | 0.020 |
Why?
| | Microcirculation | 1 | 2007 | 149 | 0.020 |
Why?
| | Suicide | 1 | 2014 | 656 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2007 | 189 | 0.020 |
Why?
| | Cell Survival | 1 | 2010 | 1120 | 0.020 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2006 | 136 | 0.020 |
Why?
| | Evidence-Based Practice | 1 | 2008 | 229 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2013 | 4193 | 0.020 |
Why?
| | Reoperation | 1 | 2008 | 573 | 0.010 |
Why?
| | Oxygen | 1 | 2010 | 931 | 0.010 |
Why?
| | Transplantation Chimera | 1 | 2005 | 54 | 0.010 |
Why?
| | Eosinophilia | 1 | 2007 | 218 | 0.010 |
Why?
| | Models, Biological | 1 | 2012 | 1783 | 0.010 |
Why?
| | Ischemia | 1 | 2007 | 409 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2012 | 2475 | 0.010 |
Why?
| | Inpatients | 1 | 2008 | 500 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 767 | 0.010 |
Why?
| | Biopsy | 1 | 2007 | 1129 | 0.010 |
Why?
| | Respiratory System | 1 | 2005 | 157 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1483 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4295 | 0.010 |
Why?
| | Kinetics | 1 | 2006 | 1670 | 0.010 |
Why?
| | Respirovirus | 1 | 2002 | 6 | 0.010 |
Why?
| | Virus Cultivation | 1 | 2002 | 29 | 0.010 |
Why?
| | Influenza B virus | 1 | 2002 | 44 | 0.010 |
Why?
| | Immunoenzyme Techniques | 1 | 2002 | 219 | 0.010 |
Why?
| | Pneumonia | 1 | 2007 | 639 | 0.010 |
Why?
| | Influenza A virus | 1 | 2002 | 107 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2014 | 5778 | 0.010 |
Why?
| | Chronic Disease | 1 | 2007 | 1793 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2008 | 3284 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 1910 | 0.010 |
Why?
| | Immunotherapy | 1 | 2005 | 641 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2010 | 2691 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2004 | 1457 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2004 | 2833 | 0.010 |
Why?
| | Inflammation | 1 | 2005 | 2837 | 0.010 |
Why?
|
|
Zamora's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|